Back to Search Start Over

Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study

Authors :
Sina, F
Cassani, C
Comerio, C
De Ponti, E
Zanellini, F
Delle Marchette, M
Roversi, G
Jaconi, M
Arbustini, E
Urtis, M
Dell'Oro, C
Zambetti, B
Paniga, C
Acampora, E
Negri, S
Lazzarin, S
Cesari, S
Spinillo, A
Kotsopoulos, J
Fruscio, R
Sina, Federica
Cassani, Chiara
Comerio, Chiara
De Ponti, Elena
Zanellini, Francesca
Delle Marchette, Martina
Roversi, Gaia
Jaconi, Marta
Arbustini, Eloisa
Urtis, Mario
Dell'Oro, Cristina
Zambetti, Benedetta
Paniga, Cristiana
Acampora, Eleonora
Negri, Serena
Lazzarin, Sara
Cesari, Stefania
Spinillo, Arsenio
Kotsopoulos, Joanne
Fruscio, Robert
Sina, F
Cassani, C
Comerio, C
De Ponti, E
Zanellini, F
Delle Marchette, M
Roversi, G
Jaconi, M
Arbustini, E
Urtis, M
Dell'Oro, C
Zambetti, B
Paniga, C
Acampora, E
Negri, S
Lazzarin, S
Cesari, S
Spinillo, A
Kotsopoulos, J
Fruscio, R
Sina, Federica
Cassani, Chiara
Comerio, Chiara
De Ponti, Elena
Zanellini, Francesca
Delle Marchette, Martina
Roversi, Gaia
Jaconi, Marta
Arbustini, Eloisa
Urtis, Mario
Dell'Oro, Cristina
Zambetti, Benedetta
Paniga, Cristiana
Acampora, Eleonora
Negri, Serena
Lazzarin, Sara
Cesari, Stefania
Spinillo, Arsenio
Kotsopoulos, Joanne
Fruscio, Robert
Publication Year :
2022

Abstract

OBJECTIVE: To describe tubal histopathological abnormalities in women with germline BRCA1/2 mutations and in controls. METHODS: Consecutive women with BRCA1/2 mutations undergoing bilateral salpingo-oophorectomy between 2010 and 2020 in two centers (San Gerardo Hospital, Monza and San Matteo Hospital, Pavia) were considered in this analysis and compared with controls who had the same surgical procedure for benign conditions. Frequency of p53 signature, serous tubal intraepithelial carcinoma, and high-grade serous ovarian cancer were compared between the two groups. RESULTS: A total of 194 women with pathogenic BRCA1/2 mutations underwent prophylactic salpingo-oophorectomy. Of these, 138 women (71%) had a completely negative histological examination, while in 56 (29%) patients an ovarian or tubal alteration was reported. Among controls, 84% of patients had a p53wt signature, while 16% had a p53 signature. There was no difference in the frequency of a p53 signature between cases and controls; however, women with BRCA1/2 mutations were more likely to have pre-malignant or invasive alterations of tubal or ovarian epithelium (p=0.015). Among mutation carriers, older age both at genetic testing and at surgery was associated with an increased risk of having malignancies (OR=1.07, p=0.006 and OR=1.08, p=0.004, respectively). The risk of malignancy seems to be increased in patients with a familial history of high-grade serous ovarian cancer. Previous therapy with tamoxifen was significantly more frequent in patients with malignant lesions (40.0% vs 21.3%, p=0.006). CONCLUSION: We found that a p53 signature is a frequent finding both in BRCA1/2 mutation carriers and in controls, while pre-invasive and invasive lesions are more frequent in BRCA1/2 mutation carriers. Genetic and clinical characteristics are likely to affect the progression to malignancy.

Details

Database :
OAIster
Notes :
STAMPA, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1308942318
Document Type :
Electronic Resource